Cargando…

β1-blocker in sepsis

BACKGROUND: The use of ultrashort-acting β1-blockers recently has attracted attention in septic patients with non-compensatory tachycardia. We summarized the metabolic and hemodynamic effects and the clinical evidence of ultrashort-acting β1-blockers. MAIN BODY: A recent meta-analysis showed that ul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Daisuke, Sato, Ryota, Nishida, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105957/ https://www.ncbi.nlm.nih.gov/pubmed/33964987 http://dx.doi.org/10.1186/s40560-021-00552-w

Ejemplares similares

β-blockers in septic shock: are we there yet?
por: Cruz, Madalena Coutinho, et al.
Publicado: (2017)

Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes
por: Hasegawa, Daisuke, et al.
Publicado: (2019)

Systematic review of use of β-blockers in sepsis
por: Chacko, Cyril Jacob, et al.
Publicado: (2015)

Avoidance of β-blockers in patients who use stimulants is not supported by good evidence
por: Wilson, Tyler, et al.
Publicado: (2022)

Different Non-selective β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Comparative Analysis of Three Machine-Learning Techniques and Conventional Techniques for Predicting Sepsis-Induced Coagulopathy Progression
por: Hasegawa, Daisuke, et al.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Clinical Significance of MicroRNAs in Patients with Sepsis: Protocol for a Systematic Review and Meta-Analysis
por: Hasegawa, Daisuke, et al.
Publicado: (2019)

Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint
por: Fitzgerald, Paul J
Publicado: (2012)

Recombinant scorpion toxins: Focus on four-disulfide peptide blockers of Kv1-channels
por: Nekrasova, Oksana, et al.
Publicado: (2017)

Heart disease: recruitment of MEF2 activity by β−blockers wards off cardiomyocyte death
por: Hashemi, S, et al.
Publicado: (2015)

Galápagosization of sepsis management in Japan: a nationwide survey of current practices
por: Yamakawa, Kazuma, et al.
Publicado: (2020)

Association between the β-blocker use and patients with sepsis: a cohort study
por: Yang, Qilin, et al.
Publicado: (2023)

Sepsis in PD-1 light
por: Monneret, Guillaume, et al.
Publicado: (2016)

The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?
por: Marshall, John C
Publicado: (2002)

The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?
por: Abraham, Edward
Publicado: (2002)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Who's Afraid of the Big Bad Wolf? Safety of Beta-Blockers in COPD
por: Ambrosio, Giuseppe, et al.
Publicado: (2019)

Impact of Blood Type O on Mortality of Sepsis Patients: A Multicenter Retrospective Observational Study
por: Hasegawa, Daisuke, et al.
Publicado: (2020)

Effect of β-blockers on mortality in patients with sepsis: A propensity-score matched analysis
por: Ge, Cheng-Long, et al.
Publicado: (2023)

Urine sTREM-1 assessment in diagnosing sepsis and sepsis-related acute kidney injury
por: Derive, Marc, et al.
Publicado: (2011)

Death to sepsis: targeting apoptosis pathways in sepsis
por: Wheeler, Derek S
Publicado: (2009)

CFTR Channel Pharmacology: Novel Pore Blockers Identified by High-throughput Screening
por: Sheppard, David N.
Publicado: (2004)

The International Sepsis Forum's frontiers in sepsis: high cardiac output should be maintained in severe sepsis
por: Vincent, Jean-Louis
Publicado: (2003)

The International Sepsis Forum's frontiers in sepsis: high cardiac output should not be maintained in severe sepsis
por: Sharma, Vinay K, et al.
Publicado: (2003)

Hyperinsulinemia-euglycemia therapy: a useful tool in treating calcium channel blocker poisoning
por: Levine, Michael D, et al.
Publicado: (2006)

The challenge of sepsis
por: Levy, Mitchell M
Publicado: (2004)

β-Blockers in sepsis: protocol for a systematic review and meta-analysis of randomised control trials
por: Duan, Erick H, et al.
Publicado: (2016)

The Surviving Sepsis Campaign sepsis change bundles and clinical practice
por: Dellinger, R Phillip, et al.
Publicado: (2005)

Comparison of ivabradine plus β-blockers versus β-blocker therapy only
por: Aalbers, J
Publicado: (2010)

Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis
por: Wang, Zexu, et al.
Publicado: (2023)

From the International Pediatric Sepsis Conference 2005 to the Sepsis-3 Consensus
por: de Souza, Daniela Carla, et al.
Publicado: (2018)

Does low angiopoietin-1 predict adverse outcome in sepsis?
por: David, Sascha, et al.
Publicado: (2010)

Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017)

Targeting RAGE in sepsis
por: van Zoelen, Marieke AD, et al.
Publicado: (2008)

Myocardial protection in sepsis
por: Shakar, Simon, et al.
Publicado: (2008)

Antithrombin in sepsis revisited
por: Levi, Marcel
Publicado: (2005)

Neuroimmune perspectives in sepsis
por: Ulloa, Luis, et al.
Publicado: (2009)

Sepsis and the broken endothelium
por: Shapiro, Nathan I, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pb820r21mov6grp0rr7bd90c7d